Announcements Trials
Browse Landscape

Phase

Phase 2 9Phase 1 3Phase 3 1Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Breast Neoplasms 12Glioblastoma 2Squamous Cell Carcinoma of Head and Neck 1Prostatic Neoplasms 1Ovarian Neoplasms 1Oligodendroglioma 1Neoplasm Metastasis 1Medulloblastoma 1Inflammatory Breast Neoplasms 1Her2 Positive Metastatic Breast Cancer 1Head and Neck Neoplasms 1HER2 Positive Metastatic Breast Cancer 1Gliosarcoma 1Familial ependymoma 1Colorectal Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Ovarian Epithelial 1Breast Neoplasms, Male 1Brain Neoplasms 1Astrocytoma 1

Interventions

Temozolomide 26Bevacizumab 14Radiosurgery 12Radiotherapy 9pembrolizumab 8Carboplatin 8Trastuzumab 6temsirolimus 5Sirolimus 5Erlotinib Hydrochloride 5abemaciclib 4Paclitaxel 4Irinotecan 4Capecitabine 4tipifarnib 3Sorafenib 3Radiation 3Mental Status and Dementia Tests 3Ipilimumab 3Everolimus 3Aminolevulinic Acid 3130-nm albumin-bound paclitaxel 3tucatinib 2pertuzumab 2fludarabine 2durvalumab 2alovudine 2alectinib 2Vorinostat 2Surgical Procedures, Operative 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Brain Neoplasms × Lapatinib × Clear all
NCT00099060 2014-01-27

Lapatinib in Treating Patients With Recurrent Glioblastoma Multiforme

National Cancer Institute (NCI)

Phase 1/2 Completed
24 enrolled
CNSSarcoma

Brain Neoplasms, Glioblastoma, Central Nervous System Neoplasms, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡